Portal de Periódicos da CAPES

Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials

2016; Elsevier BV; Volume: 68; Issue: 24 Linguagem: Inglês

10.1016/j.jacc.2016.09.936

1558-3597

João Pedro Ferreira, Kévin Duarte, Todd Graves, Michael R. Zile, William T. Abraham, Fred A. Weaver, JoAnn Lindenfeld, Faı̈ez Zannad,

Health Systems, Economic Evaluations, Quality of Life

The Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions document was issued as a guidance for industry and for the Food and Drug Administration. The Expedited Access Pathway was designed as a new program for medical devices that demonstrated the potential to address unmet medical needs for life threatening or irreversibly debilitating conditions. The Food and Drug Administration would consider assessments of a device's effect on intermediate endpoints that, when improving in a congruent fashion, are reasonably likely to predict clinical benefit. The purpose of this review is to provide evidence to support the use of 3 such intermediate endpoints: natriuretic peptides, such as N-terminal pro–B-type natriuretic peptide/B-type natriuretic peptide, the 6-min walk test distance, and health-related quality of life in heart failure.